Joseph J Eron Jr
Overview
Explore the profile of Joseph J Eron Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
4113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Gunthard H, et al.
JAMA
. 2024 Dec;
333(7):609-628.
PMID: 39616604
Importance: New data and new antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Objective: To provide updated recommendations for HIV treatment and...
2.
Gandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, et al.
JAMA
. 2022 Dec;
329(1):63-84.
PMID: 36454551
Importance: Recent advances in treatment and prevention of HIV warrant updated recommendations to guide optimal practice. Objective: Based on a critical evaluation of new data, to provide clinicians with recommendations...
3.
Nance R, Delaney J, Floyd J, Saag M, Moore R, Keruly J, et al.
AIDS
. 2022 Feb;
36(6):903-905.
PMID: 35220349
To assess atrial fibrillation risk factors in people with HIV, we identified incident atrial fibrillation in a large clinical cohort of people receiving care. Compared with 970 controls without atrial...
4.
Fischer 2nd W, Eron Jr J, Holman W, Cohen M, Fang L, Szewczyk L, et al.
Sci Transl Med
. 2021 Dec;
14(628):eabl7430.
PMID: 34941423
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression to severe coronavirus disease 2019...
5.
Saag M, Gandhi R, Hoy J, Landovitz R, Thompson M, Sax P, et al.
JAMA
. 2020 Oct;
324(16):1651-1669.
PMID: 33052386
Importance: Data on the use of antiretroviral drugs, including new drugs and formulations, for the treatment and prevention of HIV infection continue to guide optimal practices. Objective: To evaluate new...
6.
Landovitz R, Li S, Eron Jr J, Grinsztejn B, Dawood H, Liu A, et al.
Lancet HIV
. 2020 Jun;
7(7):e472-e481.
PMID: 32497491
Background: Long-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical development for HIV prevention and treatment. We aimed to assess the terminal phase pharmacokinetics and safety of...
7.
Gupta S, Post F, Arribas J, Eron Jr J, Wohl D, Clarke A, et al.
AIDS
. 2019 Apr;
33(9):1455-1465.
PMID: 30932951
Objective: Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has been associated with improvement in markers of renal dysfunction in individual randomized trials; however, the comparative incidence of clinically...
8.
Eron Jr J, Lelievre J, Kalayjian R, Slim J, Wurapa A, Stephens J, et al.
Lancet HIV
. 2018 Dec;
PMID: 30555051
Background: Current treatment for HIV-infected individuals with renal failure on haemodialysis frequently requires complex regimens with multiple pills. A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide...
9.
Saag M, Benson C, Gandhi R, Hoy J, Landovitz R, Mugavero M, et al.
JAMA
. 2018 Jul;
320(4):379-396.
PMID: 30043070
Importance: Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. Objective: To evaluate new data and treatments and incorporate this information into updated recommendations for initiating...
10.
Ludema C, Edmonds A, Cole S, Eron Jr J, Adedimeji A, Cohen J, et al.
AIDS Care
. 2018 Jul;
30(11):1360-1367.
PMID: 29962235
In the South, people living with HIV experience worse health outcomes than in other geographic regions, likely due to regional political, structural, and socioeconomic factors. We describe the neighborhoods of...